Australia markets closed

Evoke Pharma Inc (EV00.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
2.7400-0.1200 (-4.20%)
At close: 08:02AM CET
Full screen
Previous close2.8600
Open2.7400
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range2.7400 - 2.7400
52-week range1.4300 - 14.7240
Volume640
Avg. volume10
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

    Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31,

  • GlobeNewswire

    Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

    SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET

  • GlobeNewswire

    Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

    Distinguished event features the year’s best abstracts and invited speakers in their fieldsSOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Reducing Real-World